JP2016518338A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016518338A5 JP2016518338A5 JP2016503137A JP2016503137A JP2016518338A5 JP 2016518338 A5 JP2016518338 A5 JP 2016518338A5 JP 2016503137 A JP2016503137 A JP 2016503137A JP 2016503137 A JP2016503137 A JP 2016503137A JP 2016518338 A5 JP2016518338 A5 JP 2016518338A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- dhcq
- disease
- atorvastatin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- XFICNUNWUREFDP-UHFFFAOYSA-N 2-[4-[(7-chloroquinolin-4-yl)amino]pentylamino]ethanol Chemical compound ClC1=CC=C2C(NC(CCCNCCO)C)=CC=NC2=C1 XFICNUNWUREFDP-UHFFFAOYSA-N 0.000 claims 5
- 229960005370 atorvastatin Drugs 0.000 claims 3
- XUKUURHRXDUEBC-KAYWLYCHSA-N atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 206010053219 Non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 208000001756 Virus Disease Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 200000000018 inflammatory disease Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- FJLGEFLZQAZZCD-JUFISIKESA-N (3S,5R)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-JUFISIKESA-N 0.000 claims 1
- 206010001897 Alzheimer's disease Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 206010011401 Crohn's disease Diseases 0.000 claims 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 claims 1
- 206010012601 Diabetes mellitus Diseases 0.000 claims 1
- 241000711549 Hepacivirus C Species 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 claims 1
- 206010062060 Hyperlipidaemia Diseases 0.000 claims 1
- 206010022489 Insulin resistance Diseases 0.000 claims 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N Lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 1
- 208000002780 Macular Degeneration Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- AJLFOPYRIVGYMJ-INTXDZFKSA-N Mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 claims 1
- 229950009116 Mevastatin Drugs 0.000 claims 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N Pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims 1
- 229960002965 Pravastatin Drugs 0.000 claims 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N Pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N Rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 1
- RYMZZMVNJRMUDD-HGQWONQESA-N Simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 1
- 201000001320 atherosclerosis Diseases 0.000 claims 1
- 201000008739 coronary artery disease Diseases 0.000 claims 1
- 201000009846 fatty liver disease Diseases 0.000 claims 1
- 229960003765 fluvastatin Drugs 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 201000009673 liver disease Diseases 0.000 claims 1
- 229960004844 lovastatin Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 229960002797 pitavastatin Drugs 0.000 claims 1
- 201000004681 psoriasis Diseases 0.000 claims 1
- 229960000672 rosuvastatin Drugs 0.000 claims 1
- 229960002855 simvastatin Drugs 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
Claims (8)
- 炎症性疾患または炎症を伴う疾患の治療に使用される医薬組成物であって、
有効な用量のＤＨＣＱ（desethylhydroxychloroquine）または薬学的に許容されるその塩若しくはエステルを含むことを特徴とする医薬組成物。 - 前記ＤＨＣＱまたは薬学的に許容されるその塩若しくはエステルを、有効な１日投与量である４００〜６００ｍｇ含むことを特徴とする請求項１に記載の医薬組成物。
- ５５０ｍｇ以上のＤＨＣＱを含むことを特徴とする請求項１に記載の医薬組成物。
- 前記医薬組成物は、更にスタチンを含むことを特徴とする請求項１〜３の何れか一項に記載の医薬組成物。
- 前記スタチンは、アトルバスタチン、フルバスタチン、ロバスタチン、メバスタチン、ピタバスタチン、プラバスタチン、ロスバスタチン、シンバスタチンの１種または複数種のスタチンであることを特徴とする請求項４に記載の医薬組成物。
- 前記医薬組成物は、更にアトルバスタチンを含むことを特徴とする請求項１に記載の医薬組成物。
- 前記医薬組成物は、有効な１日投与量である５０〜１０００ｍｇのＤＨＣＱと、有効な１日投与量である１〜２５０ｍｇのアトルバスタチンとを含むことを特徴とする請求項６に記載の医薬組成物。
- 前記炎症性疾患または炎症を伴う疾患は、多発性硬化症、全身性エリテマトーデス、関節リウマチ、クローン病、乾癬、自己免疫性肝炎、変形性関節症、アルツハイマー病、黄斑変性症、ＩＩ型糖尿病、アテローム性動脈硬化症、冠動脈疾患、非アルコール性脂肪性肝炎（ＮＡＳＨ）、代謝症候群、ヒト免疫不全ウィルス感染症、Ｃ型肝炎ウィルス感染症、サイトメガロウィルス感染症、脂肪肝疾患、非アルコール性脂肪性肝疾患、インスリン抵抗性、高脂血症、及びそれらの組み合わせからなる群より選択されることを特徴とする請求項１〜７の何れか一項に記載の医薬組成物。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361791320P | 2013-03-15 | 2013-03-15 | |
| US61/791,320 | 2013-03-15 | ||
| PCT/US2014/029557 WO2014144944A1 (en) | 2013-03-15 | 2014-03-14 | Desethylhydroxychloroquine for the treatment of diseases associated with inflammation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016518338A JP2016518338A (ja) | 2016-06-23 |
| JP2016518338A5 true JP2016518338A5 (ja) | 2017-04-06 |
| JP6434487B2 JP6434487B2 (ja) | 2018-12-05 |
Family
ID=51529979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016503137A Expired - Fee Related JP6434487B2 (ja) | 2013-03-15 | 2014-03-14 | 炎症を伴う疾患の治療のためのデスエチルヒドロキシクロロキン |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US9616057B2 (ja) |
| EP (1) | EP2967062A4 (ja) |
| JP (1) | JP6434487B2 (ja) |
| CN (2) | CN105228453B (ja) |
| WO (1) | WO2014144944A1 (ja) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9616057B2 (en) * | 2013-03-15 | 2017-04-11 | The Board Of Trustees Of The Leland Stanford Junior University | Desethylhydroxychloroquine for the treatment of diseases associated with inflammation |
| EP4050616A1 (en) | 2015-04-09 | 2022-08-31 | Diane R. Mould | Systems and methods for patient-specific dosing |
| WO2017189686A1 (en) * | 2016-04-27 | 2017-11-02 | The Board Of Regents Of The University Of Texas System | Nurr1 activation in the treatment of metabolic disorders and as an exercise mimetic |
| CN108095767B (zh) * | 2018-01-19 | 2020-10-02 | 无锡海斯凯尔医学技术有限公司 | 组织炎症活动度检测装置 |
| GB2594918A (en) * | 2020-03-30 | 2021-11-17 | Blackhawk Partners Ltd | A pharmaceutical composition comprising hydroxychloroquine, chloroquine, or metabolite thereof |
| EP3892275A1 (en) * | 2020-04-08 | 2021-10-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Aerosolization of hcq or its metabolites for the treatment of lung infections |
| JP2021051776A (ja) * | 2020-12-15 | 2021-04-01 | 株式会社トプコン | 医療情報処理システム及び医療情報処理方法 |
| JP2024520741A (ja) * | 2021-06-04 | 2024-05-24 | ジェノベート バイオテクノロジー カンパニー リミテッド | Ｓ－ヒドロキシクロロキンを用いた抗リン脂質症候群の処置 |
| CN114689770A (zh) * | 2022-03-02 | 2022-07-01 | 上海长征医院 | 直接检测尿液中羟氯喹及其三种代谢产物的方法及检测试剂盒 |
| CN115068478B (zh) * | 2022-07-22 | 2024-01-09 | 上海医药工业有限公司 | 磷酸萘酚喹在制备治疗自身免疫性疾病药物中的应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US341592A (en) * | 1886-05-11 | Eeubex a | ||
| CA784722A (en) * | 1968-05-07 | W. Dennis Emery | Desethylhydroxychloroquine as an anti-inflammatory agent | |
| US3019169A (en) * | 1958-06-23 | 1962-01-30 | Sterling Drug Inc | Salicylate dry shell coating of dry 4-aminoquinoline core, and dry-compressing tablet-making process |
| US3415932A (en) | 1965-05-18 | 1968-12-10 | Sterling Drug Inc | 7 - chloro - 4 - [4-(2-hydroxyethylamino)-1-methylbutylamino]quinoline; anti-inflammatory compositions and method using same |
| US20040229908A1 (en) | 1999-07-13 | 2004-11-18 | Jodi Nelson | Compositions and methods for the treatment of Parkinson's disease and tardive dyskinesias |
| US20060014786A1 (en) * | 2002-05-17 | 2006-01-19 | Rajeev Raut | Opthalmic pharmaceutical compositions and methods for treating ocular inflammation |
| US20070003636A1 (en) | 2003-01-22 | 2007-01-04 | Francois Mach | Statins (HMG-COA reductase inhibitors) as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent |
| CA2528774A1 (en) * | 2003-06-20 | 2005-01-27 | Coley Pharmaceutical Gmbh | Small molecule toll-like receptor (tlr) antagonists |
| US20050026979A1 (en) * | 2003-07-31 | 2005-02-03 | Maha Ghazzi | Methods for treating inflammation and inflammation-associated diseases with a statin and ether |
| US8440695B2 (en) | 2005-11-09 | 2013-05-14 | St Jude Children's Research Hospital | Use of chloroquine to treat metabolic syndrome |
| FR2898057B1 (fr) * | 2006-03-06 | 2008-07-04 | Centre Nat Rech Scient | Utilisation de composes derives de l'adenine pour le traitement de lupus |
| WO2008021210A2 (en) | 2006-08-11 | 2008-02-21 | Combinatorx, Incorporated | Methods and compositions for the treatment of neurodegenerative disorders |
| EP3087988A3 (en) * | 2008-10-06 | 2017-03-01 | Idera Pharmaceuticals, Inc. | Use of inhibitors of toll-like receptors in the prevention and treatment of hypercholesterolemia and hyperlipidemia and diseases related thereto |
| WO2010127313A1 (en) * | 2009-05-01 | 2010-11-04 | Edenspace Systems Corporation | Hmg-coa secondary metabolites and uses thereof |
| WO2011051966A2 (en) | 2009-10-12 | 2011-05-05 | Ipca Laboratories Limited | Pharmaceutical compositions for the treatment/prophylaxis of non-alcoholic fatty liver disease |
| WO2012071042A1 (en) * | 2010-11-24 | 2012-05-31 | Government Of The U.S.A. Represented By The Secretary, Dept. Of Health & Human Services | Compositions and methods for treating or preventing lupus |
| WO2014031769A2 (en) | 2012-08-21 | 2014-02-27 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of diseases associated with inflammation |
| US9616057B2 (en) * | 2013-03-15 | 2017-04-11 | The Board Of Trustees Of The Leland Stanford Junior University | Desethylhydroxychloroquine for the treatment of diseases associated with inflammation |
-
2014
- 2014-03-14 US US14/214,307 patent/US9616057B2/en not_active Expired - Fee Related
- 2014-03-14 CN CN201480028469.4A patent/CN105228453B/zh not_active Expired - Fee Related
- 2014-03-14 WO PCT/US2014/029557 patent/WO2014144944A1/en active Application Filing
- 2014-03-14 CN CN201810522358.9A patent/CN108434138A/zh active Pending
- 2014-03-14 EP EP14763776.3A patent/EP2967062A4/en not_active Withdrawn
- 2014-03-14 JP JP2016503137A patent/JP6434487B2/ja not_active Expired - Fee Related
-
2017
- 2017-03-01 US US15/446,860 patent/US9931335B2/en not_active Expired - Fee Related
-
2018
- 2018-02-21 US US15/901,601 patent/US20180311231A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016518338A5 (ja) | ||
| RU2022100434A (ru) | Фармацевтические композиции, содержащие epa и сердечно-сосудистое средство, и способы их применения | |
| JP2022116083A5 (ja) | ||
| HRP20210485T1 (hr) | Fitokompleksi iz citrus bergamia | |
| JP2018536710A5 (ja) | ||
| JP2016523847A5 (ja) | ||
| WO2011083999A3 (ko) | 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물 | |
| JP2017536363A5 (ja) | ||
| JP2007277267A5 (ja) | ||
| JP2016521279A5 (ja) | ||
| JP2016538248A5 (ja) | ||
| JP2010047616A5 (ja) | ||
| AR081032A1 (es) | Formulacion farmaceutica en forma de comprimidos de dos capas que comprenden inhibidor de hmg-coa reductasa e irbesartan | |
| RU2017104149A (ru) | Генетические маркеры для прогнозирования ответа на терапию поднимающими уровень hdl или имитирующими hdl агентами | |
| JP2014511891A5 (ja) | ||
| RU2008141240A (ru) | Замещенные производные хроманола и их применение | |
| Kwon et al. | Cholesterol lowering effects of low-dose statins in Korean patients | |
| JP2016511753A5 (ja) | ||
| IN2015DN02966A (ja) | ||
| JP2007530528A5 (ja) | ||
| Volkov et al. | Study of therapeutic properties of the prototype injection of a hepatoprotective drug based on flavolignans of silybum marianum | |
| JP2017538758A5 (ja) | ||
| AR101724A1 (es) | COMPOSICIÓN FARMACÉUTICA Y COMBINACIÓN TERAPÉUTICA QUE COMPRENDE UN INHIBIDOR DE LA PROTEÍNA DE TRANSFERENCIA DEL ÉSTER COLESTERILO E INHIBIDORES DE LA HMG CoA REDUCTASA | |
| JP2014521738A5 (ja) | ||
| CL2015003561A1 (es) | Composición farmacéutica para administración por vía oral para su uso para la prevención y/o el tratamiento de una enfermedad cardiovascular. |